3 assets in Inappropriate ADH Syndrome

Therapeutic assets addressing Inappropriate ADH Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tolvaptan Inappropriate ADH Syndrome	King's College Hospital NHS Trust	P3	BBB (74)
Empagliflozin Inappropriate ADH Syndrome	University Hospital, Basel, Switzerland	P4	BB (71)
Urea Inappropriate ADH Syndrome	Helbert Rondon Berrios, MD, MS	P2	CCC (53)